Literature DB >> 15467267

Quantitative estimation of myocardial fibrosis based on receptor occupancy for beta2-adrenergic receptor agonists in rats.

Satoru Tanaka1, Yasunori Momose, Masaru Tsutsui, Tomoyuki Kishida, Junji Kuroda, Nobuo Shibata, Takemi Yoshida, Ryoichi Yamagishi.   

Abstract

To develop beta2-adrenergic receptor (AR) agonists with higher selectivity, it is essential to evaluate the cardiac side effects which are the most serious side effects of this class of drugs. We studied receptor occupancy of beta1-ARs in rats as a possible cause for the side effect of beta2-AR agonists, namely myocardial fibrosis. Myocardial fibrosis in rats was observed on Day 7 after the administration of salbutamol and terbutaline, both of which are selective beta2-AR agonists, at higher dose levels. To evaluate receptor occupancy, plasma concentrations of (R)-salbutamol and (R)-terbutaline, plasma protein binding and the EC50 for chronotropic effects in rats were determined. Based on the plasma concentrations, the plasma protein binding and EC50, receptor occupancy-time profiles were constructed. The relationship between the receptor occupancy-time profile under the curve, the AUCphi, and the degree of myocardial fibrosis was evaluated with a multiple correlation analysis. Myocardial fibrosis was significantly correlated (r2 > 0.78) to the AUCphi with the threshold above approximately 50%, but not to plasma concentrations. These results indicate that the receptor occupancy theory is also useful for the evaluation of the chronotropic side effects of beta2-AR agonists.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467267     DOI: 10.2131/jts.29.179

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  2 in total

1.  Investigation of distribution and elimination of terbutaline sulfate in the perfused rat liver preparation.

Authors:  Selma Sahin; Yasemin Karabey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

Review 2.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.